Exalenz reports quick pace of US installations

The company has installed 32 BreathID systems in the US since the start of sales in August 2010.

Exalenz Bioscience Ltd. (TASE:EXEN) has successfully installed 32 of its BreathID diagnostic systems in the US since sales began in August 2010. The systems detect the H. pylori bacteria, a cause of stomach ulcers

In addition to the immediate revenue from the systems, Exalenz believes that most income will come from sales of the test systems over several years. The company has received 37 orders for BreathID kits from a range of clients, including general practitioners, gastrointestinal clinics, and hospitals.

Earlier this month, Exalenz announced the first installation of a system at the emergency room of George Washington University Hospital in Washington DC. The company believes that emergency rooms and intensive care wards will be important markets for the BreathID system. The company considers the US market as a primary strategic market, and is focusing most of its marketing efforts there.

As part of the marketing strategy in the US, Exalenz has set up a sales network and signed three nationwide distribution agreements with two of the three largest US medical products distributors.

Exalenz CEO Steven Eitan said, "The rapid pace of sales of the system in the US, as well as the quality of the medical centers with which we signed agreements for the sale and use of the BreathID system, is very encouraging, and indicates strong current demand for the company's systems and their technological edge."

Exalenz's share price rose 2.1% today to NIS 0.91, giving a market cap of NIS 118 million.

Published by Globes [online], Israel business news - www.globes-online.com - on March 24, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018